文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

血糖变异系数与脓毒症诱导性凝血病的相关性及危险因素分析

[Correlation between glycemic variability coefficient and sepsis-induced coagulopathy and analysis of risk factors].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2026-01-01
一句话结论脓毒症患者入ICU 24小时内血糖变异系数与SIC风险呈线性正相关,高血糖CV、高BMI和CRRT是SIC独立危险因素,血糖CV对SIC有一定预测价值。

该回顾性病例对照研究纳入440例脓毒症患者,按入ICU 24小时内血糖CV四分位数分组,以SIC为主要结局。校正混杂因素后,血糖CV每增加10%,SIC风险增加(OR=1.049,95%CI 1.024-1.074,P<0.001);Q4组(CV≥31.5%)较Q1组SIC风险显著升高(OR=2.739,95%CI 1.427-5.255,P=0.002)。RCS分析显示线性剂量反应关系。高血糖CV、高BMI和CRRT为SIC独立危险因素。血糖CV预测SIC的AUC为0.624,切点24.5%时敏感度70.6%、特异度52.1%。

要点

  • 脓毒症患者入ICU 24小时内血糖CV每增加10%,SIC风险增加(OR=1.049,95%CI 1.024-1.074,P<0.001)。
  • 血糖CV≥31.5%者(Q4组)较CV<19.5%者(Q1组)SIC风险显著升高(OR=2.739,95%CI 1.427-5.255,P=0.002)。
  • 高血糖CV(OR=1.049)、高BMI(OR=1.175)和CRRT(OR=3.286)是脓毒症患者发生SIC的独立危险因素。
  • 血糖CV预测SIC的AUC为0.624,切点24.5%时敏感度70.6%、特异度52.1%,预测价值有限。
  • 血糖CV与SIC风险呈线性剂量反应关系(整体P<0.001,非线性P=0.828),亚组分析未发现显著交互作用。

适用人群与场景

  • 2021年7月至2024年6月秦皇岛市第一医院重症医学科收治的脓毒症患者,共440例。

诊断标准与关键阈值

  • 以入ICU 24小时内血糖变异系数(CV)为暴露变量,按四分位数分组:Q1(CV<19.5%)、Q2(19.5%≤CV<26.0%)、Q3(26.0%≤CV<31.5%)、Q4(CV≥31.5%)。
  • 以脓毒症诱导性凝血病(SIC)为主要结局,按是否发生SIC分为SIC组(160例)和非SIC组(280例)。
  • 血糖CV预测SIC的ROC曲线切点为24.5%,敏感度70.6%,特异度52.1%。

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:回顾性病例对照研究,单中心,样本量440例脓毒症患者。
  • 主要终点:校正混杂因素后,血糖CV每增加10%,SIC风险增加(OR=1.049,95%CI 1.024-1.074,P<0.001);Q4组较Q1组SIC风险显著升高(OR=2.739,95%CI 1.427-5.255,P=0.002)。
  • 剂量反应:RCS分析显示血糖CV与SIC风险呈线性关系(整体P<0.001,非线性P=0.828)。
  • 独立危险因素:高血糖CV(OR=1.049,95%CI 1.024-1.074,P<0.001)、高BMI(OR=1.175,95%CI 1.106-1.248,P<0.001)、CRRT(OR=3.286,95%CI 1.561-6.919,P=0.002)。
  • 预测价值:血糖CV预测SIC的AUC为0.624,切点24.5%,敏感度70.6%,特异度52.1%。
  • 亚组分析:血糖CV与性别、年龄、糖尿病、APACHE II评分、SOFA评分、使用血管活性药物、使用糖皮质激素或抗凝治疗之间无显著交互作用。

证据类型、等级与局限

  • 证据类型:回顾性病例对照研究,单中心,样本量440例。
  • 局限:原文未提及证据等级;设计本身为回顾性、单中心,可能存在选择偏倚和未测量混杂;血糖CV预测SIC的AUC仅0.624,预测价值有限。

对床旁实践的改变

  • 对脓毒症患者,入ICU 24小时内监测血糖CV可能有助于早期识别SIC高风险患者,尤其当CV≥31.5%时SIC风险显著增加。
  • 高BMI和接受CRRT的脓毒症患者SIC风险更高,应加强凝血功能监测。
  • 血糖CV对SIC的预测价值有限(AUC 0.624),不能单独作为启动抗凝或诊断SIC的依据。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the association between glycemic variability coefficient (CV) and sepsis-induced coagulopathy (SIC), analyze the related risk factors for SIC in septic patients, and further explore the clinical value of glycemic CV as a potential predictor for SIC.

METHODS: A retrospective case-control study was conducted. General data, laboratory findings, therapeutic interventions, and disease severity scores of septic patients admitted to the Department of Critical Care Medicine of the First Hospital of Qinhuangdao from July 2021 to June 2024 were collected. Blood glucose CV within 24 hours of admission was used as the exposure variable, and SIC served as the primary outcome. Patients were divided into Q1, Q2, Q3, and Q4 groups according to quartiles of glycemic CV within 24 hours of intensive care unit (ICU) admission, with Q1 as the reference. Baseline clinical characteristics were compared among the four groups. Multivariate logistic regression was performed to analyze the effect of glycemic CV on SIC occurrence after adjusting for various confounders. Subgroup analyses were used to explore potential interaction effects and further verify the robustness of the results. A restricted cubic spline model was applied to examine the dose-response relationship between glycemic CV and SIC. Patients were divided into SIC and non-SIC groups based on the presence of SIC. Univariate analysis was used to identify risk factors for SIC, and significant variables were entered into binary logistic regression to determine independent risk factors. Receiver operator characteristic curve (ROC curve) was plotted to assess the predictive value of glycemic CV for SIC.

RESULTS: A total of 440 patients with sepsis were enrolled, including 110 in Q1 (glycemic CV<19.5%), 109 in Q2 (19.5%≤glycemic CV<26.0%), 111 in Q3 (26.0%≤glycemic CV<31.5%), and 110 in Q4 (glycemic CV≥31.5%). Multivariate logistic regression showed that after adjustment for confounders, each 10% increase in glycemic CV was associated with an increased risk of SIC [odds ratio (OR)=1.049, 95% confidence interval (95%CI) was 1.024-1.074, P<0.001]. Compared with Q1, the risk of SIC remained significantly higher in Q4 (OR=2.739, 95%CI was 1.427-5.255, P=0.002). Restricted cubic spline (RCS) analysis revealed a linear dose-response relationship between glycemic CV and SIC risk (overall P<0.001, nonlinear P=0.828), with the risk increasing linearly as glycemic CV rose. Subgroup analyses showed no significant interaction between glycemic CV and sex, age, diabetes, Acute Physiology and Chronic Health Evaluation II(APACHE II), Sequential Organ Failure Assessment (SOFA), use of vasoactive agents, use of corticosteroids, or anticoagulant therapy, consistently supporting elevated glycemic CV as a risk factor for SIC. Among the 440 patients, 280 were in the non-SIC group and 160 in the SIC group. Multivariate logistic regression including significant variables from univariate analysis identified high glycemic CV (OR=1.049, 95%CI was 1.024-1.074, P<0.001), high body mass index (BMI; OR=1.175, 95%CI was 1.106-1.248, P<0.001), and continuous renal replacement therapy (CRRT; OR=3.286, 95%CI was 1.561-6.919, P=0.002) as independent risk factors for SIC. ROC curve analysis showed that the area under the curve (AUC) of glycemic CV for predicting SIC was 0.624, with a cutoff value of 24.5%, yielding a specificity of 52.1% and sensitivity of 70.6%.

CONCLUSIONS: There is a positive linear relationship between glycemic CV and the risk of SIC in septic patients. High glycemic CV, high BMI, and CRRT are independent risk factors for SIC. Glycemic CV has certain predictive value for SIC, and monitoring glycemic CV may facilitate early identification and prevention of SIC, thereby improving patient outcomes.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Zhang L, Liu X. [Correlation between glycemic variability coefficient and sepsis-induced coagulopathy and analysis of risk factors]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2026. PMID: 42875237. doi:10.3760/cma.j.cn121430-20260331-00150

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。